Epstein David R sold $27K of TEM

Epstein David R sold 370 shares of Tempus AI, Inc. (TEM) at $74.29 on 2026-11-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Epstein David R
Published Nov 4, 2026, 9:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 9:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TEM
Bearish
medium confidence
Mentioned
$TEM
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TEMBearishLow
01

Why it matters

The transaction is a primary disclosure but of modest size, likely causing only a slight price dip.

02

Market read

Provides fresh insider‑sale data for TEM, useful for short‑term monitoring but low trading significance.

03

What to watch

Potential upcoming data releases or partnership announcements could offset the sale's impact.

Relevance 2/10Novelty 2/10Timing: same day filing

Background

SEC Form 4 filing discloses a director's sale under a pre‑arranged 10b5‑1 plan.

Company-level read

Ticker impact

$TEMBearishMedium confidence
Context

Director Epstein sold 370 shares for $27,487 via a 10b5‑1 plan, reducing his holdings to 30,474 shares.

Expected impact

likely slight downward pressure as the market prices the insider sale

Evidence & confidence

A $27k sale by a director is small relative to market cap, but 10b5‑1 sales are often viewed as neutral to mildly negative.

Market effects

Minimal impact on the AI/health‑tech sector; insider sales are routine.

No broader regional effect.

Limited to investors tracking Tempus AI.

Counterpoint

The sale could be unrelated to fundamentals; the stock may still be undervalued.

Key entities

  • Tempus AI, Inc.

    US‑listed AI‑driven healthcare data company (NASDAQ: TEM).

  • Epstein David R.

    Director of Tempus AI who executed the sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Med

Tempus CEO Eric Lefkofsky: A Blood Draw Can Catch Returning Cancer 6 to 12 Months Before a Scan

Tempus CEO Eric Lefkofsky reported a record quarter with 23% revenue growth, driven by 32% growth in cancer testing and 33% in data & AI applications. The company signed three $100M+ deals, including with Merck and Bristol Myers Squibb. Tempus claims its blood tests can detect cancer recurrence 6-12 months earlier than scans, leveraging its 600-petabyte data trove and 8,000 hospital integrations. The company is acquiring Personalis to expand into recurrence detection.

$TEMMedAI 8/10

BTIG raises Tempus AI stock price target to $100 on data deals

BTIG raised its price target for Tempus AI (NASDAQ:TEM) to $100, citing strong quarterly results, raised guidance, and significant data deals, including a $200M agreement with Bristol Myers Squibb. The company reported 50% revenue growth and positive adjusted EBITDA. Other analysts also raised price targets, noting strong performance in data and diagnostics segments.

$TEMLow

Jefferies upgrades Tempus AI stock rating to hold, raises price target to $70

Jefferies upgraded Tempus AI (TEM) from Underperform to Hold, raising its price target to $70. The stock, currently at $78.48, has gained 43% in six months. The firm cited strong revenue growth, strategic collaborations, and FDA approval plans. Tempus reported Q3 2026 earnings of $0.07 per share, beating estimates, with revenue up 23% to $411.5 million. Needham raised its price target to $89, citing data business growth.

$TEMMed

Tempus AI Inc (TEM) Q3 2026 Earnings Call Highlights: Revenue Jumps 23%

Tempus AI Inc (TEM) reported Q3 2026 revenue of $411M, up 23%. CEO Lefkofsky expects sustainable 25%+ growth, with oncology and data segments driving performance. The company anticipates mid-2027 breakeven for Personalis' MRD test and predicts strong market share in MRD. Tempus also highlighted long-term data business commitments and AI-driven customer stickiness.